Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scan trick could cut contrast dye use by 40% in lung clot tests

NCT ID NCT07342374

Diagnosis Sponsor: Hospital Queen Elizabeth, Malaysia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a small change in how CT scans are done for people with suspected lung blood clots. By moving the scan's focus area to a different blood vessel, doctors aimed to use less contrast dye (30 ml instead of 50 ml) without losing image quality. The trial involved 72 adults and compared the new method to the standard one. The goal was to see if the new approach still gives clear pictures while reducing the amount of dye needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

72 people

The number who actually took part.

Started

Feb 2023

Finished

Dec 2024

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All patients scheduled for a Computed Tomography Pulmonary Angiography (CTPA) examination. * Provision of written informed consent by the subject, guardian, or medical specialist. * Patients with an upper extremity intravenous (IV) line using a 16-20 gauge cannula. * Patients with a stable heart rate between 60 and 120 beats per minute (bpm). Exclusion Criteria: * Pregnancy, breastfeeding, or use of non-reliable methods of contraception. * Patients with impaired renal function, including acute kidney injury or chronic kidney disease (CKD) with an eGFR less than 30 mL/min/1.73m². * Patients with a lower extremity IV line, as this bypasses the Superior Vena Cava (SVC) and results in bolus tracking technique failure. * Patients with a heart rate lower than 60 bpm or higher than 120 bpm. * Patients with a cannula size of 22g or smaller, as it cannot accommodate the high flow rate (4 mL/s) required by the power injector. * Patients with severe cardiac impairment or congenital heart disease. * Patients with a Body Mass Index (BMI) exceeding 35 kg/m², as severe obesity causes beam hardening effects that degrade image quality.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pulmonary artery embolism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pulmonary embolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pulmonary artery embolism Pulmonary embolism (PE)

Contacts and locations

Locations

  • Hospital Queen Elizabeth

    Kota Kinabalu, Sabah, 88200, Malaysia

More trials for these conditions

Other studies related to the condition(s) this trial covers.